Biomarker screening and intervention window for iliac vein stent restenosis: a systematic review of evidence-based advances
- 1Department of Vascular Surgery, Fudan University Zhongshan Hospital Qingpu Branch, 1158 East Park Road, Shanghai, 201700 China
Abstract
Iliac vein stent restenosis (ISR) remains a significant complication following stent placement for iliac vein compression syndrome (Rajput et al. in Cardiovasc Diagn Ther. 11:1103–1115, 2021) and post-thrombotic syndrome, with reported 1-year incidence rates of 18%-30%. This systematic review synthesizes evidence from the past five years to evaluate advances in predictive biomarker discovery, the concept of an optimal intervention window, and emerging therapeutic strategies. A comprehensive literature search identified 127 relevant studies. Our analysis reveals that combined biomarker models incorporating inflammatory cytokines (e.g., IL-6), microRNA panels (e.g., miR-92a/126), and coagulation-fibrosis markers (e.g., TAT, TGF-β1) show promising predictive value (pooled AUC up to 0.84), though clinical validation remains limited. Pathophysiological and computational modeling suggests a critical "subclinical stenosis phase" may exist 3-6 months post-stenting, during which interventions might be more effective, but robust clinical trial data supporting specific timing is scarce. While drug-eluting stents reduce short-term ISR rates, long-term safety concerns persist. Novel approaches, including bioresorbable materials and targeted biological therapies, are primarily in preclinical stages. This review underscores the urgent need for standardized biomarker validation, prospective trials to define intervention timing, and interdisciplinary collaboration to translate mechanistic insights into improved clinical outcomes for ISR prevention and management.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s13019-026-04027-7.
Related
- From Evidence to Intervention: A Systematic, Multi-Stakeholder Approach to Developing and Prioritizing Diagnostic Excellence Interventions Across a 14-Site Hospital Medicine Collaborative
- Long-term incidence and predictors of in-stent restenosis after chronic total occlusion percutaneous coronary intervention: a cohort study.
- Qualitative clinician feedback on a systematic urinary incontinence screening and patient education intervention in primary care
- SCFA Alterations in IBS Subtypes: Systematic Evidence and Future Prospects for Biomarker-Based Diagnosis in India.
- Nomogram for predicting post-percutaneous coronary intervention restenosis in patients with coronary artery disease and diabetes: a retrospective study
BibTeX
@article{wang2026biomarker,
title = {{Biomarker screening and intervention window for iliac vein stent restenosis: a systematic review of evidence-based advances}},
author = {Xiaojun Wang and Xu Li and Jianjun Liu and Yue Tao and Tao Wang and Limeng Li},
journal = {Journal of Cardiothoracic Surgery},
year = {2026},
month = jul,
doi = {10.1186/s13019-026-04027-7},
url = {https://doi.org/10.1186/s13019-026-04027-7},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Biomarker screening and intervention window for iliac vein stent restenosis: a systematic review of evidence-based advances
AU - Xiaojun Wang
AU - Xu Li
AU - Jianjun Liu
AU - Yue Tao
AU - Tao Wang
AU - Limeng Li
PY - 2026
DA - 2026/07/31
JO - Journal of Cardiothoracic Surgery
DO - 10.1186/s13019-026-04027-7
UR - https://doi.org/10.1186/s13019-026-04027-7
AB - Iliac vein stent restenosis (ISR) remains a significant complication following stent placement for iliac vein compression syndrome (Rajput et al. in Cardiovasc Diagn Ther. 11:1103–1115, 2021) and post-thrombotic syndrome, with reported 1-year incidence rates of 18%-30%. This systematic review synthesizes evidence from the past five years to evaluate advances in predictive biomarker discovery, the concept of an optimal intervention window, and emerging therapeutic strategies. A comprehensive literature search identified 127 relevant studies. Our analysis reveals that combined biomarker models incorporating inflammatory cytokines (e.g., IL-6), microRNA panels (e.g., miR-92a/126), and coagulation-fibrosis markers (e.g., TAT, TGF-β1) show promising predictive value (pooled AUC up to 0.84), though clinical validation remains limited. Pathophysiological and computational modeling suggests a critical "subclinical stenosis phase" may exist 3-6 months post-stenting, during which interventions might be more effective, but robust clinical trial data supporting specific timing is scarce. While drug-eluting stents reduce short-term ISR rates, long-term safety concerns persist. Novel approaches, including bioresorbable materials and targeted biological therapies, are primarily in preclinical stages. This review underscores the urgent need for standardized biomarker validation, prospective trials to define intervention timing, and interdisciplinary collaboration to translate mechanistic insights into improved clinical outcomes for ISR prevention and management. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s13019-026-04027-7.
SN - 1749-8090
ER -